A light yellow transparent liquid.
Product Name：Irinotecan injection, Camptosar
Nombre del Producto: Irinotecán solución inyectable
Specification: 40mg/2ml 100mg/5ml
Standard: State Standard
Irinotecan is an antineoplastic agent. It works by interfering with the production of proteins necessary for cancer cell growth and reproduction.
Anemia (>90%),Leukopenia (>90%),Neutropenia (>90%),Thrombocytopenia (>90%),Elevated bilirubin (88%),Diarrhea (85%),Nausea (79%),Asthenia (70%),Abdominal pain (63%),Vomiting (60%),Alopecia (43%),Fever (42%),Constipation (41%),Anorexia (34%),Mucositis (32%),Pain (31%),Dyspnea (28%),Cough (27%),Dizziness (23%),Infection (22%),Rash (19%)
Abdominal fullness (10%),AST increased (10%),Dyspepsia (10%),,Edema (10%),Ascites/jaundice (9%),Vasodilation (9%),Thromboembolism (9%),Hypotension (6%),Neutropenic fever (2-6%)
Frequency Not Defined
Hereditary fructose intolerance (d/t sorbitol)
The drug should be administered under the supervision of an experienced cancer chemotherapy physician in facility with appropriate personnel and equipment to diagnose and manage the complications resulting from the therapy.
Early & late forms of severe diarrhea that may be mediated by different mechanisms have been reported. Following the irinotecan infusion, atropine can be used to treat or ameliorate the early diarrhea (occurring shortly after the infusion), which may be accompanied by cholinergic symptoms, including intestinal hyperperistalsis. Late diarrhea (after 24 hr of irinotecan infusion) can be life threatening because it can lead to dehydration, electrolyte imbalance, or sepsis. It should be treated promptly with loperamide, and patients should be given fluid and electrolytes if they become dehydrated or antibiotics if they develop fever.
Severe myelosuppression may occur
Mechanism of Action
Binds to topoisomerase I to produce double-strand breaks in DNA
Half-Life: 6-12 hr; SN-38 10-20 hr
Pleak Plasma Concentration: 1660 ng/mL; SN-38 26.3 ng/mL
Protein Bound: 30-68%; SN-38 95%
Vd: 110-234 L/m²
Metabolism: hepatic, to SN-38; SN-38 is further metabolized by UGT1A1
Clearance: 13-14 L/hr/m²
Excretion: urine, feces
China irinotecan Hcl injection manufacturer,China irinotecan Hcl injection suppliers,irinotecan Hcl injection from China professional pharmaceutical factory,Oncology Drugs , Oncology Nursing Drug , Oncology And Supplementary Drug , Oncology Drugs Manufacturers , Oncology Drugs Suppliers , China Oncology Drugs , Irinotecan Hcl injection
We are considered as one of the leading manufacturers and suppliers of irinotecan injection. With the aid of our technologically advanced manufacturing section, we are able to offer customers irinotecan injection products which are tested on various quality parameters in order to supply flawless range at the customers' end.